- Home
- ALXO vs PULM Comparison
ALXO vs PULM Comparison
Compare ALXO & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- PULM
- Stock Information
- Founded
- ALXO 2015
- PULM 2003
- Country
- ALXO United States
- PULM United States
- Employees
- ALXO N/A
- PULM N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- PULM Health Care
- Exchange
- ALXO Nasdaq
- PULM Nasdaq
- Market Cap
- ALXO 24.0M
- PULM 20.5M
- IPO Year
- ALXO 2020
- PULM N/A
- Fundamental
- Price
- ALXO $1.17
- PULM $4.89
- Analyst Decision
- ALXO Strong Buy
- PULM
- Analyst Count
- ALXO 6
- PULM 0
- Target Price
- ALXO $3.30
- PULM N/A
- AVG Volume (30 Days)
- ALXO 1.7M
- PULM 11.7K
- Earning Date
- ALXO 08-12-2025
- PULM 08-06-2025
- Dividend Yield
- ALXO N/A
- PULM N/A
- EPS Growth
- ALXO N/A
- PULM N/A
- EPS
- ALXO N/A
- PULM N/A
- Revenue
- ALXO N/A
- PULM $369,000.00
- Revenue This Year
- ALXO N/A
- PULM N/A
- Revenue Next Year
- ALXO N/A
- PULM $134.88
- P/E Ratio
- ALXO N/A
- PULM N/A
- Revenue Growth
- ALXO N/A
- PULM N/A
- 52 Week Low
- ALXO $0.40
- PULM $1.78
- 52 Week High
- ALXO $2.59
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- ALXO 75.79
- PULM 41.32
- Support Level
- ALXO $0.80
- PULM $4.44
- Resistance Level
- ALXO $1.04
- PULM $5.09
- Average True Range (ATR)
- ALXO 0.11
- PULM 0.29
- MACD
- ALXO 0.05
- PULM 0.02
- Stochastic Oscillator
- ALXO 96.85
- PULM 39.47
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).